Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

Global Cancer Statistics, 2002

2005 • 17,966 citations

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1999 • 8,737 citations

Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

2003 • 6,072 citations

The causal relation between human papillomavirus and cervical cancer

2002 • 3,451 citations

Human papillomavirus and cervical cancer

2007 • 2,789 citations

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

2006 • 1,766 citations

Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update

2007 • 1,654 citations

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

2004 • 1,624 citations

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

2009 • 1,580 citations

Prevalence of HPV Infection Among Females in the United States

2007 • 1,567 citations

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

2007 • 1,558 citations

Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells

2002 • 1,305 citations

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

2007 • 1,287 citations

Humoral Immunity Due to Long-Lived Plasma Cells

1998 • 1,223 citations

Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia

2008 • 817 citations

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

1995 • 683 citations

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

2003 • 680 citations

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

2006 • 480 citations

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

2009 • 468 citations

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

2007 • 456 citations

Are booster immunisations needed for lifelong hepatitis B immunity?

2000 • 431 citations

A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica

2005 • 405 citations

Comparison of the immunogenicity and safety ofCervarix™ andGardasil^®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

2009 • 386 citations

Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection

2010 • 356 citations

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

2009 • 347 citations

Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.

1995 • 283 citations

Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms

2006 • 267 citations

Immunobiology of HPV and HPV vaccines

2008 • 254 citations

Hepatitis A booster vaccination: is there a need?

2003 • 242 citations

Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529

2003 • 236 citations

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

2007 • 236 citations

Vaccination in the elderly: an immunological perspective

2009 • 232 citations

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus

1996 • 221 citations

Monophosphoryl Lipid A as an Adjuvant

1995 • 214 citations

The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta‐analysis

2002 • 205 citations

Hepatitis B vaccine – do we need boosters?

2003 • 203 citations

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

2009 • 196 citations

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

2008 • 172 citations

In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection

2010 • 167 citations

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

2010 • 164 citations

INFUSION THROMBOPHLEBITIS

1975 • 159 citations

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

2008 • 152 citations

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆

2009 • 151 citations

Age-related decline in immunity: implications for vaccine responsiveness

2008 • 150 citations

Antigen dependent and independent mechanisms that sustain serum antibody levels

2003 • 141 citations

Persistence of specific antibodies after hepatitis B vaccination

1988 • 123 citations

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature

2008 • 117 citations

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

2009 • 109 citations

Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening

2008 • 97 citations

Immunosenescence and Influenza Vaccine Efficacy

2009 • 95 citations

Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®

2009 • 82 citations

Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration

1997 • 33 citations